Anti-Mullerian hormone levels of uterine artery embolization in the treatment of patients suffering Myomectomy and uterine leiomyoma

Comparison of anti-Mullerian hormone level in two treatment methods, myomectomy and uterine artery embolization, in patients with uterine fibroids

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014020114333N17

Enrollment

Registered

2014-02-12

Start date

2013-09-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

utrine fibroids and bleeding. Other specified noninflammatory disorders of uterus

Interventions

Intervention 1: In the second treatment group, patients will be treated through myomectomy. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery. Intervention 2: In

Treatment - Surgery

In the second treatment group, patients will be treated through myomectomy. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery.

In the first treatment group, patients will be treated through uterine artery embolization. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery.

Eligibility

Sex/Gender

Female

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 25-40 years; having debilitating complaints such as severe bleeding due to myoma, uterine enlargement up to 16 weeks pregnancy, anemia and pressure on the pelvic organs of patients which candidates her for myomectomy. Exclusion criteria: probability of pelvic malignancies, ovarian pathologies, pelvic infections; desiring fertility, contrast sensitivity, renal disorders, and systemic autoimmune disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Duration of returning to work. Timepoint: 6 months after discharge. Method of measurement: Asking the patient.;Anti-Mullerian hormone level. Timepoint: Baseline and 6 months after surgery. Method of measurement: Measurement in the laboratory.;Patients’ complaints (hot flush, bleeding, pelvic pain and pressure, urinary problems, etc.). Timepoint: 6 months after intervention. Method of measurement: Asking the patient.;Pain level. Timepoint: One week after intervention. Method of measurement: Asking the patient.;Duration of hospitalization. Timepoint: Discharge date. Method of measurement: Based on patient records.;Cost of treatment. Timepoint: Discharge date. Method of measurement: Based on patient records.	—

Measure

Time frame

Duration of returning to work. Timepoint: 6 months after discharge. Method of measurement: Asking the patient.;Anti-Mullerian hormone level. Timepoint: Baseline and 6 months after surgery. Method of measurement: Measurement in the laboratory.;Patients’ complaints (hot flush, bleeding, pelvic pain and pressure, urinary problems, etc.). Timepoint: 6 months after intervention. Method of measurement: Asking the patient.;Pain level. Timepoint: One week after intervention. Method of measurement: Asking the patient.;Duration of hospitalization. Timepoint: Discharge date. Method of measurement: Based on patient records.;Cost of treatment. Timepoint: Discharge date. Method of measurement: Based on patient records.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026